title: Alternative dosage schedules with HPV virus-like particle vaccines.
abstract: HPV vaccines can prevent multiple cancers in women and men. Difficulties in the cost and completion of the three-dose vaccine series have led to considerations of alternative dose schedules. In clinical trials, three doses given within a 12-month period versus the standard 6-month period yielded comparable results, and immunogenicity appears comparable with two doses in adolescent females compared to the three-dose series in adult females. While the data are generally supportive of moving to a two-dose vaccine schedule among young female adolescents, the adoption of a two-dose vaccine schedule still poses a potential risk to the strength and longevity of the immune response. Public health authorities implementing a two-dose vaccine schedule should devise risk management strategies to minimize the potential impact on cancer prevention.
authors.affiliation: University of Cambridge, Cambridge, UK.
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Stanley
authors.forename: Staci L
authors.initials: SL
authors.lastname: Sudenga
authors.forename: Anna R
authors.initials: AR
authors.lastname: Giuliano
mesh_terms: D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007114:Immunization / Q000379:methods*; D007115:Immunization Schedule; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D058425:Vaccines, Virus-Like Particle / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D053918:Papillomavirus Vaccines; D058425:Vaccines, Virus-Like Particle
keywords: HPV vaccination; dose schedule; dosing; immunogenicity; virus-like particle